Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Overview
The Journal of Cystic Fibrosis is the official publication of the European Cystic Fibrosis Society. It is a leading scientific journal dedicated to advancing knowledge and understanding of cystic fibrosis, a genetic disorder affecting the lungs and other organs. The journal publishes high-quality research articles, reviews, and clinical studies, providing a platform for researchers, clinicians, and healthcare professionals to share their findings and contribute to the improvement of patient care and outcomes in cystic fibrosis.
Details
Details
Abbr.
J Cyst Fibros
Publisher
Elsevier
Start
2002
End
Continuing
Frequency
Quarterly
p-ISSN
1569-1993
e-ISSN
1873-5010
Country
Netherlands
Language
English
Specialty
Pulmonary Medicine
Metrics
Metrics
h-index / Ranks: 3601
91
SJR / Ranks: 1159
2043
CiteScore / Ranks: 1874
8.80
JIF / Ranks: 1476
5.2
Recent Articles
1.
Wood C, Moheet A, Vigers T, Granados A, Lorenz A, Hanley E, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40089409
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been highly effective for improving pulmonary disease and nutritional outcomes. However, the effect of this therapy on glycemic control in people with cystic fibrosis related diabetes...
2.
Vonk S, Terheggen-Lagro S, Haarman E, Hashimoto S, Maitland-van der Zee A, Mathot R, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40089408
Background: The clinical efficacy of elexacaftor-tezacaftor-ivacaftor (ETI) in children with cystic fibrosis (cwCF) is variable; some respond, while others do not or have side effects. The pharmacokinetics (PK) of ETI...
3.
Gravelle J, Desai S, Dong K, Quon B
J Cyst Fibros
. 2025 Mar;
PMID: 40074570
Fatigue is common among adults with cystic fibrosis (awCF) and may be associated with systemic inflammation. This study examines systemic inflammation, measured by C-reactive protein (CRP), and fatigue, assessed using...
4.
Kieninger E, Munidasa S, Curdy M, Streibel C, Zanette B, Woods J, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40069051
Introduction: Functional magnetic resonance imaging (MRI) of the lung usually assesses lung impairment as ventilation defect percentage (VDP). However, VDP only reflects the overall burden of disease and does not...
5.
Baromeo S, van der Meer R, van Rossen R, Wilms E
J Cyst Fibros
. 2025 Mar;
PMID: 40069050
Background: Recent studies revealed that some people with cystic fibrosis (pwCF) receiving the full dose of Elexacaftor/Tezacaftor/Ivacaftor (ETI) experience adverse events (AEs), leading to discontinuation or dose adjustments of their...
6.
Chouchana L, Collier M, Martin C, Burgel P, Treluyer J
J Cyst Fibros
. 2025 Mar;
PMID: 40058987
Objectives: Recent therapeutic advances, mainly with the advent of CFTR modulators, have been associated with an increasing number of pregnancies in females with cystic fibrosis (fwCF). This study aimed to...
7.
Cafora M, Dobi D, William J, Forti F, Belleri L, Loberto N, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40055113
Cystic fibrosis is caused by biallelic mutations in the gene encoding the CFTR conductor channel. The recent approval of the Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy has marked a milestone in the management...
8.
9.
Conti J, Angyal D, Kleinfelder K, Latorre R, Calicchia M, Farinazzo A, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40023749
No abstract available.
10.
Everhart R, Saavedra M, Ford C, Gibson S, Reid F, Muther E, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39986976
Background: Symptoms of depression and anxiety can contribute to lower medical treatment adherence. Given that people with cystic fibrosis (PWCF) have higher rates of depressive and anxiety symptoms than those...